UK stem cell research group launched
A new initiative to use stem cells for the safety testing of potential drugs has been launched in London, UK. Marking its official inauguration, Stem Cells for Safer Medicines (SC4SM) has invited proposals from research partners interested in developing techniques to use stem cells for early safety testing of new pharmaceutical products.
SC4SM is an independent, not-for-profit company founded via a consortium of public and pharmaceutical industry investment, including three drug majors: UK-based GlaxoSmithKline, Anglo-Swedish AstraZeneca and Switzerland's Roche. The group stated that it is initiated by the UK's Department of Health and the Association of the British Pharmaceutical Industry. The new collaboration is also supported by the Department for Innovation, Universities and Skills, the Scottish government, the Medical Research Council and the Biotechnology and Biological Sciences Research Council.
UK Science Minister Ian Pearson said the new initiative "is a core part of the government's 10-year strategy for stem cell research in the UK."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze